The 6th Annual Chief Residents Summit on Obesity (CRSO) Webinar Series
Sponsorship and Support: This webinar is sponsored by Primary Care Education Consortium, in collaboration with the Primary Care Metabolic Group. It is supported by educational grants from Novo Nordisk and Eli Lilly and Company.
Accreditation: The Southern Medical Association (SMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The Southern Medical Association designates this enduring material for a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificates of participation are provided to attendees not eligible for AMA PRA Category 1 CreditsTM. The term of approval is from February 27, 2026, to August 28, 2026.
Faculty Disclosure Information: Southern Medical Association (SMA) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by SMA are required to disclose all financial relationships with any ineligible company within the past 24 months to SMA. All financial relationships reported are identified as relevant and mitigated by SMA in accordance with the Standards for Integrity and Independence in Accredited CE, in advance of delivery of the activity to learners. The content of this activity was vetted by SMA to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SMA.
Stephen Brunton, MD, FAAFP – Planner and Moderator: Discloses that he serves as a consultant and speaker for Abbott Diabetes, Lilly and AstraZeneca, as a consultant for Novo Nordisk and Sanofi. He also has stock options for Paracrine.
Robert Kushner, MD – Faculty: Discloses that he serves as an advisor for Abbvie, Antag, Altimmune, Boehringer Ingelheim, Currax, Eli Lilly, Novo Nordisk, Structure and Weight Watchers. He also serves as a consultant for AstraZeneca.
Eden Miller, DO, FOMA – Faculty: Discloses that she is serves as an advisory and speaker for Abbott, Eli Lilly, Boehringer Ingelheim, Insulet, and Novo Nordisk. She also serves as a speaker for Bayer and Corcept.
Christopher Still, DO, FACN, FACP, FTOS – Faculty: Discloses that he is a consultant and speaker for Novo Nordisk and Lilly; a consultant for Currax, Boehringer Ingelheim, and Regeneron; and is contracted for research with Ethicon Endosurgery.
Donna H. Ryan, MD – Faculty: Discloses that she serves as an advisor for Abbvie, Altimmune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot/Roche, Cin Rx, Currax, Zealand, eMed, Epitomee, Structure Therapeutics, WW, Tenvie, Viking, Wondr Health, Fractyl, Gila, i20, Souffle Therapeutics, Source Bio, Lilly, Nestle, PPD, Scientific Intake, Pfizer, Protagonist, Novo Nordisk, Regeneron, and Sanofi. She also serves as a speaker for Lilly, Novo Nordisk, and Rhythm, and on the Data Monitoring Committee for Rhythm, Lilly, and Cin Rx.
Joseph Nadglowski, Jr. – Faculty: Discloses that he serves as CEO and a paid employee of the Obesity Action Coalition.
Austin Ulrich, PharmD – Planner: Has no disclosures to report.
Nora Williams, BA, MTS – Planner: Has no disclosures to report.
Glenn Talboy, Jr., MD – Content Reviewer: Has no disclosures to report.
All relevant financial relationships have been mitigated.
This CME activity includes discussion about medications not approved by the US Food and Drug Administration and uses of medications outside of their approved labeling.
Learning Objectives: After viewing this webinar, participants should be able to
• Describe obesity as a chronic, treatable disease with significant health implications.
• Implement measures beyond BMI to assess and manage obesity.
• Develop patient-centered approaches to obesity care that include patients’ preferences and individual needs.
• Integrate guideline recommendations for initiating, monitoring, and optimizing pharmacologic obesity treatment.
• Design comprehensive, individualized treatment plans for patients with overweight or obesity, including addressing obesity-related complications.
Note that, while you may complete the webinars at your convenience, you will need to complete all five chapters to receive credit.
Chapter One: Disease/Lifestyle Interventions (52 minutes)
Chapter Two: Treatment Approaches: Pharmacologic (72 minutes)
Chapter Three: Is Bariatric Surgery Still Relevant? (31 minutes)
Chapter Four: Communication & Weight Bias (36 minutes)
Chapter Five: Access & Affordability of Medications (55 minutes)
You will need to download THREE apps to fully participate in this webinar: GoodRX or GoodRX PRO, RX Saver, and Coverage Search.
To receive your certificate after watching all five chapters of the webinar, click HERE to complete the evaluation survey.
Thanks for watching our webinar!
If you have any questions, please email Nora Williams at nwilliams@pceconsortium.org.